| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2012127012 |
| Title |
Biphenyl Tricyclic Quinazoline Compounds. |
| Abstract |
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are multiple inhibitors of tyrosine kinase activity. |
| Applicant(s) |
Universita 'Degli Studi Di Padova |
| Representative Drug(s) |
D03JXD |
Drug Info
|
IC50 < 1000 nM |
Click to Show More |
[1] |
|
2
|
D06LHV
|
Drug Info
|
IC50 < 1000 nM
|
[1] |
|
3
|
D0KM7V
|
Drug Info
|
IC50 < 1000 nM
|
[1] |
| Patent ID |
WO2012101239 |
| Title |
Derivatives of Azaindazole or Diazaindazole Type As Medicament. |
| Abstract |
The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same. |
| Applicant(s) |
Pf Medicament |
| Representative Drug(s) |
D0TX1S |
Drug Info
|
IC50 = 18 nM |
Click to Show More |
[1] |
|
2
|
D0JD9Z
|
Drug Info
|
IC50 = 38 nM
|
[1] |
| Patent ID |
WO2012080284 |
| Title |
Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof. |
| Abstract |
The invention provides novel compounds having the general formula (I) wherein X1 is N or N+O-, and one of X2, X3 and X4 is N or N+-O- and the remainder of X2, X3 and X4 is C. R2, R3, R4, R5, R6. A, B and Y are as described herein. Additionally compositions compounds of Formula (I) and methods of use are further described herein. |
| Applicant(s) |
F. Hoffmann-La Roche Ag |
| Representative Drug(s) |
D0O0RB |
Drug Info
|
Ki = 0.02 nM |
Click to Show More |
[1] |
|
2
|
D0QD6T
|
Drug Info
|
Ki = 0.02 nM
|
[1] |
| Patent ID |
WO2011008788 |
| Title |
Fluoro-Substituted Compounds As Kinase Inhibitors and Methods of Use Thereof. |
| Abstract |
The present invention provides for novel compounds of Formula I and pharmaceutically acceptable salts and solvates thereof which have kinase inhibitor activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating and preventing a Bcr-Abl, c-Kit or PDGF-R mediated disorder for which one or more kinase inhibitor is indicated, including neoplasia such as chronic myelogenous leukemia or gastrointestinal stromal tumors. The present invention also provides for processes of making the compounds of Formula I, including salts and solvates thereof, and pharmaceutical compositions comprising the same. |
| Applicant(s) |
Zhang, Dawei |
| Representative Drug(s) |
D0RT8M |
Drug Info
|
IC50 < 100 nM |
[1] |
| Patent ID |
WO2014108021 |
| Title |
Fluorocyclobutanylimidazole Compounds. |
| Abstract |
Provided are fluorocyclobutanylimidazole compounds of formula (I) and N-oxides, pharmaceutically acceptable salt or prodrugs thereof. Also provided are the preparation method thereof and intermediates. |
| Applicant(s) |
Terrabay Pharmaceuticals, Inc |
| Patent ID |
WO2014102378 |
| Title |
Azaindole Derivatives As Inhibitors of Protein Kinases. |
| Abstract |
The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders. |
| Applicant(s) |
Oribase Pharma |
| Representative Drug(s) |
D05TYI |
Drug Info
|
Inhibition values higher than 50% = 10000 nM |
[1] |
| Patent ID |
WO2014102376 |
| Title |
Protein Kinase Inhibitors. |
| Abstract |
The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders. |
| Applicant(s) |
Oribase Pharma |
| Patent ID |
WO2014088519 |
| Title |
Compounds Including Map Kinase Interacting Kinases 1 and 2 (Mnk1 and Mnk2) Modulators and Abl and Abl (T315I) Inhibitors, and Uses Thereof. |
| Abstract |
The present invention relates to certain piperazine-based compounds that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b and/or as ABL or ABL (T315I) inhibitors. The invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of cancer, inflammatory and Alzheimer disease conditions, as well as methods of treatment of these disorders. |
| Applicant(s) |
Agency for Science, Technology and Research |
| Patent ID |
WO2014071378 |
| Title |
Substituted Indol-5-Ol Derivatives and Their Therapeutical Applications. |
| Abstract |
The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases. |
| Applicant(s) |
Nant Holdings Ip, Llc |
| Representative Drug(s) |
D0F4AW |
Drug Info
|
Complete % enzyme inhibition = 100 nM |
[1] |
| Patent ID |
WO2013068909 |
| Title |
N-Methyl-2-[3-((E)-2-Pyridin-2-Yl-Vinyl)-1H-Indazol-6-Ylsulfanyl]-Benzamide for The Treatment of Chronic Myelogenous Leukemia. |
| Abstract |
The present invention relates to a method of treating chronic myelogenous leukemia in a subject comprising administering to the subject a compound, such as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide, that inhibits the T315I mutation in BCR-ABL tyrosine kinase, or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition comprising a compound such as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]- benzamide, that inhibits the T315I mutation in BCR-ABL tyrosine kinase, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. |
| Applicant(s) |
Pfizer Inc |
